Sunday, December 26, 2010

GSK offers UK rebate if Pfizer cancer drug better

LONDON (Reuters) - Britain's state-run health service will get a partial rebate from GlaxoSmithKline if the company's new kidney cancer drug Votrient does not match up to a rival medicine in a head-to-head clinical trial.

doctor oz

No comments:

Post a Comment